Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Budget-busters: The Shift to High-Priced Innovator Drugs in the USA



Download Budget-busters: The Shift to High-Priced Innovator Drugs in the USA

Over the last five years a fundamental shift in spending trends towards high-priced medicines, which treat substantially smaller patient populations, has been underway in the US market.


Based on an analysis of the Top 100 selling drugs in the USA, the new report Budget-busters: The Shift to High-Priced Innovator Drugs in the USA reveals that:

 

  • The median revenue per patient of the Top 100 drugs has increased from $1,260 in 2010 to $9,400 in 2014, representing an seven-fold increase
  • The median patient population size served by a Top 100 drug in 2014 is 146,000, down from 690,000 in 2010
  • There are now seven treatments priced in excess of $100,000 per patient per year in 2014, versus four in 2010

Download Budget-busters: The Shift to High-Priced Innovator Drugs in the USA

The budget-busters report was derived from Evaluate's new EvaluatePharma USA Sales, Volume and Pricing Analysis, which is now available in the service. The new content delivers an integrated, single source for USA sales, volume and pricing providing customers with a clear picture of their markets and their competitors when it comes to price. Download PDF or read more.

Press Release

Related Reports: 

EvaluatePharma World Preview 2014, Outlook to 2020

EP Vantage Pharma and Biotech Half-Year Review 2014

EP Vantage Medtech Half-Year Review 2014